Charlotte's Web Holdings Past Earnings Performance
Past criteria checks 0/6
Charlotte's Web Holdings's earnings have been declining at an average annual rate of -10.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 11.1% per year.
Key information
-10.4%
Earnings growth rate
-5.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -11.1% |
| Return on equity | -115.9% |
| Net Margin | -66.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Charlotte's Web Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 53 | -35 | 56 | 3 |
| 30 Jun 24 | 55 | -44 | 66 | 3 |
| 31 Mar 24 | 58 | -31 | 69 | 3 |
| 31 Dec 23 | 63 | -24 | 70 | 3 |
| 30 Sep 23 | 66 | -50 | 62 | 3 |
| 30 Jun 23 | 69 | -43 | 60 | 3 |
| 31 Mar 23 | 72 | -54 | 58 | 3 |
| 31 Dec 22 | 74 | -59 | 62 | 3 |
| 30 Sep 22 | 80 | -142 | 68 | 4 |
| 30 Jun 22 | 87 | -136 | 71 | 8 |
| 31 Mar 22 | 92 | -134 | 80 | 7 |
| 31 Dec 21 | 96 | -138 | 84 | 6 |
| 30 Sep 21 | 98 | -34 | 75 | 10 |
| 30 Jun 21 | 100 | -23 | 86 | 4 |
| 31 Mar 21 | 97 | -32 | 87 | 5 |
| 31 Dec 20 | 95 | -31 | 88 | 6 |
| 30 Sep 20 | 91 | -35 | 102 | 1 |
| 30 Jun 20 | 91 | -46 | 92 | 3 |
| 31 Mar 20 | 94 | -29 | 83 | 2 |
| 31 Dec 19 | 95 | -16 | 74 | 2 |
| 30 Sep 19 | 93 | 6 | 60 | 2 |
| 30 Jun 19 | 86 | 10 | 50 | 1 |
| 31 Mar 19 | 78 | 11 | 42 | 1 |
| 31 Dec 18 | 70 | 12 | 35 | 1 |
| 30 Sep 18 | 61 | 11 | 29 | 1 |
| 30 Jun 18 | 54 | 11 | 24 | 1 |
| 31 Mar 18 | 46 | 9 | 21 | 1 |
| 31 Dec 17 | 40 | 7 | 17 | 1 |
| 31 Dec 16 | 15 | 1 | 8 | 0 |
Quality Earnings: 6CW is currently unprofitable.
Growing Profit Margin: 6CW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6CW is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare 6CW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6CW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 6CW has a negative Return on Equity (-115.94%), as it is currently unprofitable.